|Application ||WB, ICC, E|
|Other Accession||NP_004731, 17978509|
|Calculated MW||Predicted: 13 kDa |
Observed: 14 kDa
|Application Notes||TIAF Antibody can be used for detection of TIAF by Western blot at 1 µg/mL.|
|Target/Specificity||TIAF; Two alternatively spliced transcript variants encoding different isoforms have been identified.|
|Reconstitution & Storage||TIAF antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||TIAF Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Inhibits the cytotoxic effects of TNF-alpha and overexpressed TNF receptor adapters TRADD, FADD, and RIPK1. Involved in TGF-beta1 inhibition of IkappaB-alpha expression and suppression of TNF-mediated IkappaB-alpha degradation.|
|Tissue Location||Not detectable in normal kidney and liver. Up- regulated in chronic and acute allograft rejection: expressed in the inflammatory infiltrate and in tubular epithelial cells|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
TIAF Antibody: TIAF-1 (TGFB1-induced anti-apoptotic factor 1), also known as MYO18A, is a TGFB1-induced anti-apoptotic factor that functions to inhibit the cytotoxic effects of TNF-alpha, TRADD and FADD. It localizes to the nucleus and significantly up-regulated in activated helper T lymphocytes (TH2) in chronic kidney and liver allograft rejection. Suppression of TIAF1 expression by siRNA prevents UV irradiation-mediated p53 phosphorylation and nuclear translocation. TIAF1 is essential in the p53- and WOX1-mediated cell death and shows an aggregation-dependent control of tumor progression and metastasis, and regulation of cell death.
Chang NS, Mattison J, Cao H, et al. Cloning and characterization of a novel transforming growth factor-beta1-induced TIAF1 protein that inhibits tumor necrosis factor cytotoxicity. Biochem. Biophys. Res. Commun. 1998; 253:743-9.
Khera S and Chang NS. TIAF1 participates in the transforming growth factor beta1--mediated growth regulation. Ann. N.Y. Acad. Sci. 2003; 995:11-21.
Van der Leij J, Van den Berg A, Albrecht EW, et al. High expression of TIAF-1 in chronic kidney and liver allograft rejection and in activated T-helper cells. Transplantation 2003; 75:2076-82.
Schultz L, Khera S, Sleve D, et al. TIAF1 and p53 functionally interact in mediating apoptosis and silencing of TIAF1 abolishes nuclear translocation of serine 15-phosphorylated p53. DNA Cell Biol. 2004; 23:67-74
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.